Current Report Filing (8-k)
August 15 2022 - 07:28AM
Edgar (US Regulatory)
0001137883 false 0001137883 2022-08-15
2022-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
August 15, 2022
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36641 |
|
20-7273918 |
(State or other jurisdiction of
incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification
No.) |
|
1325 Avenue of Americas,
28th Floor |
|
|
New York,
NY |
10019 |
| (Address of principal executive
offices) |
(Zip Code) |
(201)
488-0460
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
Common Stock, $0.00005 par value |
BCLI |
NASDAQ Stock Market LLC
(Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02. Results of Operations and Financial
Condition.
On August 15, 2022, Brainstorm Cell Therapeutics Inc. (the
“Company”) issued a press release announcing its financial and
operating results for the quarter ended June 30, 2022. A copy of
the press release is being furnished as Exhibit 99.1 to this Report
on Form 8-K.
The Company will host a live conference call and webcast at 8:00 am
ET on Monday, August 15, 2022 to discuss its second quarter 2022
financial results and business progress. A live webcast of the
conference call may be accessed by visiting the Investors &
Media section of the Company’s website at
https://ir.brainstorm-cell.com.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
BRAINSTORM CELL THERAPEUTICS INC. |
| |
|
|
| Date: August 15, 2022 |
By: |
/s/ Chaim Lebovits |
| |
|
Chaim Lebovits |
| |
Chief Executive Officer |
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Jan 2023 to Feb 2023
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Feb 2022 to Feb 2023
